| Pharmaceutical Information |
| Drug Name |
Poractant alfa |
| Drug ID |
BADD_D01801 |
| Description |
Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives. |
| Indications and Usage |
Poractant alfa is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. |
| Marketing Status |
approved |
| ATC Code |
Not Available |
| DrugBank ID |
DB09113
|
| KEGG ID |
D08402
|
| MeSH ID |
C068291
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
46575-001; 10122-510 |
| UNII |
KE3U2023NP
|
| Synonyms |
poractant alfa | poractant | Curosurf |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
129069-19-8 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
